How to buy Karuna Therapeutics stock

Karuna Therapeutics, Inc is a biotechnology business based in the US. Karuna Therapeutics shares (KRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Karuna Therapeutics employs 63 staff and has a market cap (total outstanding shares value) of 0.00.

Karuna Therapeutics share price

Use our graph to track the performance of KRTX stocks over time.

Karuna Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$69.58 - $146.97
50-day moving average	$115.58
200-day moving average	$105.50
Wall St. target price	$161.62
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-254.14

Buy Karuna Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Karuna Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Karuna Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Karuna Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-11.78%
Return on equity TTM	-18.81%
Profit margin	0%
Book value	$6.94
Market capitalisation	$3.3 billion

TTM: trailing 12 months

Shorting Karuna Therapeutics shares

There are currently 1.7 million Karuna Therapeutics shares held short by investors – that's known as Karuna Therapeutics's "short interest". This figure is 3.8% down from 1.8 million last month.

There are a few different ways that this level of interest in shorting Karuna Therapeutics shares can be evaluated.

Karuna Therapeutics's "short interest ratio" (SIR)

Karuna Therapeutics's "short interest ratio" (SIR) is the quantity of Karuna Therapeutics shares currently shorted divided by the average quantity of Karuna Therapeutics shares traded daily (recently around 182056.09492988). Karuna Therapeutics's SIR currently stands at 9.27. In other words for every 100,000 Karuna Therapeutics shares traded daily on the market, roughly 9270 shares are currently held short.

However Karuna Therapeutics's short interest can also be evaluated against the total number of Karuna Therapeutics shares, or, against the total number of tradable Karuna Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Karuna Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Karuna Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.1143% of the tradable shares (for every 100,000 tradable Karuna Therapeutics shares, roughly 114 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Karuna Therapeutics.

Find out more about how you can short Karuna Therapeutics stock.

Karuna Therapeutics share dividends

We're not expecting Karuna Therapeutics to pay a dividend over the next 12 months.

Karuna Therapeutics overview

Karuna Therapeutics, Inc. , a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Karuna Therapeutics is owned by insiders or institutions?
Currently 9.875% of Karuna Therapeutics shares are held by insiders and 83.827% by institutions. How many people work for Karuna Therapeutics?
Latest data suggests 63 work at Karuna Therapeutics. When does the fiscal year end for Karuna Therapeutics?
Karuna Therapeutics's fiscal year ends in December. Where is Karuna Therapeutics based?
Karuna Therapeutics's address is: 33 Arch Street, Boston, MA, United States, 02110 What is Karuna Therapeutics's ISIN number?
Karuna Therapeutics's international securities identification number is: US48576A1007 What is Karuna Therapeutics's CUSIP number?
Karuna Therapeutics's Committee on Uniform Securities Identification Procedures number is: 48576A100